Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

This post by MDV brings to my mind two mind boggli

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154849
(Total Views: 626)
Posted On: 01/11/2021 7:29:31 PM
Posted By: havasu78
Re: MD VIROLOGIST #72214
This post by MDV brings to my mind two mind boggling CD12 scenarios.

First, MDV offers the possibility that mortality is leronlimab dose-respondent.

Second, it occurs to me that RO could prove dose dependent life saving capability of LL, but Cytodyn doesn't have the data either because it was not done on all CD12 patients or because what RO data was collected is not in Cytodyn's possesion and is thus not presentable to the FDA.

"What I can say is in the first 100 patients there was quite a difference in RO between the two cohorts, survival data of course is forthcoming. Occupancy can vary amongst treated patient, but if those with the highest occupancy survive it could lead to fast track."

The first mind-boggling concept that MDV offers is the following:

What if the only CD12 patients who died were patients who had some "low" level of RO.

Maybe every patient who survived has RO greater than 90% at day seven, for example.

That is a p-value of of at least as good as .001.

This situation seems potentially possible to me as the dose of leronlimab was just grabbed from HIV.

Somewhat hilariously, the only way to set the dose for covid was to use the Patterson CCR5 RO data that was just rejected by the FDA for HIV!?!?!?!?!?!?

There have never been any dose limiting LL toxicities observed in humans.

Maybe covid just needs a higher dose than HIV.

We already have a very strong hypothesis that the dose method for covid is wrong and should be intravenous instead of subcutaneous.

Covid is an emergency condition. HIV is chronic.

Maybe the covid dose was not high enough and that's why the covid LL patients died. CD12 RO tests could indicate that if some LL CD12 patients had been given a higher LL dose, then all of the covid LL patients would have survived.

Well, even if that possibility doesn't make your head spin, then the second possibility could still make your head explode.

What if Cytodyn does not have the RO data that demonstrates that LL covid survival is dose dependent?

What if the reason is because CD12 RO was not done because of the split with Patterson?

What if some data is done, but Cytodyn doesn't have it because of their spat with Patterson?


(3)
(1)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us